159 related articles for article (PubMed ID: 38264525)
1. Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study.
Chen Y; Shen Q; Xiong Y; Dong M; Xu H; Li Z
Front Pharmacol; 2023; 14():1319744. PubMed ID: 38264525
[No Abstract] [Full Text] [Related]
2. Population Pharmacokinetics of Rituximab in Pediatric Patients With Frequent-Relapsing or Steroid-Dependent Nephrotic Syndrome.
Chen Y; Shen Q; Dong M; Xiong Y; Xu H; Li Z
Front Pharmacol; 2021; 12():725665. PubMed ID: 34539407
[No Abstract] [Full Text] [Related]
3. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
[TBL] [Abstract][Full Text] [Related]
4. Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial).
Nagano C; Sako M; Kamei K; Ishikura K; Nakamura H; Nakanishi K; Omori T; Nozu K; Iijima K
BMC Nephrol; 2019 Aug; 20(1):293. PubMed ID: 31375087
[TBL] [Abstract][Full Text] [Related]
5. Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.
George J; Alex S; Thomas ETA; Gracious N; Vineetha NS; Kumar S
Kidney360; 2020 May; 1(5):359-367. PubMed ID: 35369364
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial].
Zhu Y; Wu L; Wang Y; Zhu YF; Peng Y; Fang SH; Zhang LD; Deng F
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jun; 25(6):606-611. PubMed ID: 37382130
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial.
Hogan J; Perez A; Sellier-Leclerc AL; Vrillon I; Broux F; Nobili F; Harambat J; Bessenay L; Audard V; Faudeux C; Morin D; Pietrement C; Tellier S; Djeddi D; Eckart P; Lahoche A; Roussey-Kesler G; Ulinski T; Boyer O; Plaisier E; Cloarec S; Jolivot A; Guigonis V; Guilmin-Crepon S; Baudouin V; Dossier C; Deschênes G
BMJ Open; 2020 Sep; 10(9):e037306. PubMed ID: 32967877
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.
Iijima K; Sako M; Nozu K; Mori R; Tuchida N; Kamei K; Miura K; Aya K; Nakanishi K; Ohtomo Y; Takahashi S; Tanaka R; Kaito H; Nakamura H; Ishikura K; Ito S; Ohashi Y;
Lancet; 2014 Oct; 384(9950):1273-81. PubMed ID: 24965823
[TBL] [Abstract][Full Text] [Related]
9. [Incidence of hypogammaglobulinaemia in children with steroid-dependent/frequently relapsing nephrotic syndrome treated with rituximab and its association with severe infections].
Zhi YZ; Cao L; Ying DJ; Dou WJ; Gu R; Zhang JJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(6):433-439. PubMed ID: 38326055
[No Abstract] [Full Text] [Related]
10. Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases.
Pan S; Yu H; Surti A; Cheng I; Marks SD; Brogan PA; Eleftheriou D; Standing JF
Br J Clin Pharmacol; 2019 Aug; 85(8):1790-1797. PubMed ID: 31026092
[TBL] [Abstract][Full Text] [Related]
11. Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.
Bertrand Q; Mignot S; Kwon T; Couderc A; Maisin A; Cambier A; Baudouin V; Peyneau M; Deschênes G; Hogan J; Dossier C
Pediatr Nephrol; 2022 Feb; 37(2):357-365. PubMed ID: 34132894
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome.
Casiraghi F; Todeschini M; Podestà MA; Mister M; Ruggiero B; Trillini M; Carrara C; Diadei O; Villa A; Benigni A; Remuzzi G
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175393
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
[TBL] [Abstract][Full Text] [Related]
14. Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.
Liu J; Deng F; Wang X; Liu C; Sun S; Zhang R; Zhang A; Jiang X; Yan W; Dou Y; Zhang Y; Xie L; Qian B; Shen Q; Xu H
Kidney Int Rep; 2024 May; 9(5):1220-1227. PubMed ID: 38707815
[TBL] [Abstract][Full Text] [Related]
15. Rituximab Treatment for Nephrotic Syndrome in Children.
Iijima K; Sako M; Nozu K
Curr Pediatr Rep; 2015; 3(1):71-77. PubMed ID: 25741456
[TBL] [Abstract][Full Text] [Related]
16. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
17. Rituximab treatment in pediatric patients with steroid-dependent nephrotic syndrome: A tertiary hospital.
Guzmán Morais B; Ordóñez Álvarez FÁ; Santos Rodríguez F; Martín Ramos S; Fernández Novo G
An Pediatr (Engl Ed); 2022 Feb; 96(2):83-90. PubMed ID: 35144901
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for childhood refractory nephrotic syndrome.
Iijima K
Pediatr Int; 2011 Oct; 53(5):617-621. PubMed ID: 21771179
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.
Iijima K; Sako M; Kamei K; Nozu K
Pediatr Nephrol; 2018 Sep; 33(9):1449-1455. PubMed ID: 28717938
[TBL] [Abstract][Full Text] [Related]
20. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
